Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients.

Geary B, Walker MJ, Snow JT, Lee DCH, Pernemalm M, Maleki-Dizaji S, Azadbakht N, Apostolidou S, Barnes J, Krysiak P, Shah R, Booton R, Dive C, Crosbie PA, Whetton AD.

J Proteome Res. 2019 Sep 6;18(9):3369-3382. doi: 10.1021/acs.jproteome.9b00287. Epub 2019 Aug 21.

PMID:
31408348
2.

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.

Mohan S, Ayub M, Rothwell DG, Gulati S, Kilerci B, Hollebecque A, Sun Leong H, Smith NK, Sahoo S, Descamps T, Zhou C, Hubner RA, McNamara MG, Lamarca A, Valle JW, Dive C, Brady G.

Sci Rep. 2019 Aug 12;9(1):11610. doi: 10.1038/s41598-019-47489-7.

3.

How liquid biopsies can change clinical practice in oncology.

Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A.

Ann Oncol. 2019 Aug 2. pii: mdz227. doi: 10.1093/annonc/mdz227. [Epub ahead of print]

PMID:
31373349
4.

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.

Lindsay CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, Gazzaniga P, Groen HJM, Hiltermann TJN, Krebs MG, Loges S, López-López R, Muinelo-Romay L, Pantel K, Priest L, Riethdorf S, Rossi E, Terstappen L, Wikman H, Soria JC, Farace F, Renehan A, Dive C, Besse B, Michiels S.

Eur J Cancer. 2019 Aug;117:60-68. doi: 10.1016/j.ejca.2019.04.019. Epub 2019 Jun 27.

5.

Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.

Marti FEM, Jayson GC, Manoharan P, O'Connor J, Renehan AG, Backen AC, Mistry H, Ortega F, Li K, Simpson KL, Allen J, Connell J, Underhill S, Misra V, Williams KJ, Stratford I, Jackson A, Dive C, Saunders MP.

Eur J Cancer. 2019 Aug;117:48-59. doi: 10.1016/j.ejca.2019.04.029. Epub 2019 Jun 21.

PMID:
31229949
6.

Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF.

Nat Rev Cancer. 2019 Jul;19(7):415. doi: 10.1038/s41568-019-0164-2.

PMID:
31175338
7.

Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.

Tay RY, Fernández-Gutiérrez F, Foy V, Burns K, Pierce J, Morris K, Priest L, Tugwood J, Ashcroft L, Lindsay CR, Faivre-Finn C, Dive C, Blackhall F.

Ann Oncol. 2019 Jul 1;30(7):1114-1120. doi: 10.1093/annonc/mdz122.

8.

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.

Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, Smith N, Villa S, Dransfield J, Clipson A, White D, Nessa K, Ferdous S, Howell M, Gupta A, Kilerci B, Mohan S, Frese K, Gulati S, Miller C, Jordan A, Eaton H, Hickson N, O'Brien C, Graham D, Kelly C, Aruketty S, Metcalf R, Chiramel J, Tinsley N, Vickers AJ, Kurup R, Frost H, Stevenson J, Southam S, Landers D, Wallace A, Marais R, Hughes AM, Brady G, Dive C, Krebs MG.

Nat Med. 2019 May;25(5):738-743. doi: 10.1038/s41591-019-0380-z. Epub 2019 Apr 22.

PMID:
31011204
9.

Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.

Zhou C, Taylor S, Tugwood J, Simpson K, Jayson GC, Symonds P, Paul J, Davidson S, Carty K, McCartney E, Rai D, Dive C, West C.

Br J Clin Pharmacol. 2019 Aug;85(8):1781-1789. doi: 10.1111/bcp.13965. Epub 2019 Apr 13.

PMID:
30980733
10.

Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.

Parry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, Ubertini V, Ramani V, Lau M, Shanks J, Nonaka D, Oliveira P, Hambrock T, Leong HS, Dhomen N, Miller C, Brady G, Dive C, Clarke NW, Marais R, Baena E.

Eur Urol Oncol. 2019 Feb;2(1):1-11. doi: 10.1016/j.euo.2018.08.005. Epub 2018 Sep 5.

11.

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF.

Nat Rev Cancer. 2019 May;19(5):289-297. doi: 10.1038/s41568-019-0133-9. Review. Erratum in: Nat Rev Cancer. 2019 Jun 7;:.

PMID:
30926931
12.

Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.

Vassileva V, Stribbling SM, Barnes C, Carroll L, Braga M, Abrahams J, Heinzmann K, Haegeman C, MacFarlane M, Simpson KL, Dive C, Honeychurch J, Illidge TM, Aboagye EO.

EJNMMI Res. 2019 Feb 19;9(1):18. doi: 10.1186/s13550-019-0487-8.

13.

Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.

Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N.

Br J Cancer. 2019 Jan;120(2):141-153. doi: 10.1038/s41416-018-0332-2. Epub 2018 Dec 23. Review.

14.

In silico error correction improves cfDNA mutation calling.

Kim CS, Mohan S, Ayub M, Rothwell DG, Dive C, Brady G, Miller C.

Bioinformatics. 2019 Jul 15;35(14):2380-2385. doi: 10.1093/bioinformatics/bty1004.

15.

Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.

Lallo A, Gulati S, Schenk MW, Khandelwal G, Berglund UW, Pateras IS, Chester CPE, Pham TM, Kalderen C, Frese KK, Gorgoulis VG, Miller C, Blackhall F, Helleday T, Dive C.

Br J Pharmacol. 2019 Feb;176(3):436-450. doi: 10.1111/bph.14542. Epub 2018 Dec 13.

PMID:
30427531
16.

Report of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland.

Burnham A, Turnbull D, Dillon A, Dayan C, Dive C, Whitty C.

QJM. 2018 Dec 1;111(12):927-938. doi: 10.1093/qjmed/hcy194. No abstract available.

PMID:
30418641
17.

Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer.

Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C.

Nat Commun. 2018 Nov 7;9(1):4672. doi: 10.1038/s41467-018-07174-1.

18.

Will liquid biopsies improve outcomes for patients with small-cell lung cancer?

Blackhall F, Frese KK, Simpson K, Kilgour E, Brady G, Dive C.

Lancet Oncol. 2018 Sep;19(9):e470-e481. doi: 10.1016/S1470-2045(18)30455-8. Review.

PMID:
30191851
19.

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.

Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF.

Clin Cancer Res. 2018 Dec 1;24(23):5860-5872. doi: 10.1158/1078-0432.CCR-18-1569. Epub 2018 Aug 6.

PMID:
30082476
20.

Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin.

Torres-Ayuso P, Sahoo S, Ashton G, An E, Simms N, Galvin M, Leong HS, Frese KK, Simpson K, Cook N, Hughes A, Miller CJ, Marais R, Dive C, Krebs MG, Brognard J.

NPJ Genom Med. 2018 Jun 20;3:15. doi: 10.1038/s41525-018-0055-6. eCollection 2018.

21.

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.

Lallo A, Frese KK, Morrow CJ, Sloane R, Gulati S, Schenk MW, Trapani F, Simms N, Galvin M, Brown S, Hodgkinson CL, Priest L, Hughes A, Lai Z, Cadogan E, Khandelwal G, Simpson KL, Miller C, Blackhall F, O'Connor MJ, Dive C.

Clin Cancer Res. 2018 Oct 15;24(20):5153-5164. doi: 10.1158/1078-0432.CCR-17-2805. Epub 2018 Jun 25.

PMID:
29941481
22.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.

Backen AC, Lopes A, Wasan H, Palmer DH, Duggan M, Cunningham D, Anthoney A, Corrie PG, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, McNamara MG, Beare S, Bridgewater JA, Dive C, Valle JW.

Br J Cancer. 2018 Jul;119(1):27-35. doi: 10.1038/s41416-018-0132-8. Epub 2018 Jun 21.

23.

Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging.

Salem A, Mistry H, Backen A, Hodgson C, Koh P, Dean E, Priest L, Haslett K, Trigonis I, Jackson A, Asselin MC, Dive C, Renehan A, Faivre-Finn C, Blackhall F.

Clin Lung Cancer. 2018 May;19(3):239-248.e7. doi: 10.1016/j.cllc.2017.12.002. Epub 2017 Dec 11.

24.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
25.

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.

Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, D'Incalci M, Bardelli A, Siena S, Sartore-Bianchi A.

Clin Colorectal Cancer. 2018 Mar;17(1):80-83. doi: 10.1016/j.clcc.2017.10.017. Epub 2017 Nov 1.

PMID:
29195807
26.

Targeting DNA damage in SCLC.

Foy V, Schenk MW, Baker K, Gomes F, Lallo A, Frese KK, Forster M, Dive C, Blackhall F.

Lung Cancer. 2017 Dec;114:12-22. doi: 10.1016/j.lungcan.2017.10.006. Epub 2017 Oct 16. Review.

PMID:
29173760
27.

PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways.

Naidu S, Shi L, Magee P, Middleton JD, Laganá A, Sahoo S, Leong HS, Galvin M, Frese K, Dive C, Guzzardo V, Fassan M, Garofalo M.

Sci Rep. 2017 Nov 13;7(1):15441. doi: 10.1038/s41598-017-14843-6.

28.

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

Foy V, Fernandez-Gutierrez F, Faivre-Finn C, Dive C, Blackhall F.

Transl Lung Cancer Res. 2017 Aug;6(4):409-417. doi: 10.21037/tlcr.2017.07.05. Review.

29.

Circulating tumor cells and CDX models as a tool for preclinical drug development.

Lallo A, Schenk MW, Frese KK, Blackhall F, Dive C.

Transl Lung Cancer Res. 2017 Aug;6(4):397-408. doi: 10.21037/tlcr.2017.08.01. Review.

30.

Spotlight on circulating tumour cells.

Blackhall F, Dive C.

Transl Lung Cancer Res. 2017 Aug;6(4):396. doi: 10.21037/tlcr.2017.08.05. No abstract available.

31.

Progress and prospects of early detection in lung cancer.

Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C.

Open Biol. 2017 Sep;7(9). pii: 170070. doi: 10.1098/rsob.170070. Review.

32.

Molecular analysis of single circulating tumour cells following long-term storage of clinical samples.

Mesquita B, Rothwell DG, Burt DJ, Chemi F, Fernandez-Gutierrez F, Slane-Tan D, Antonello J, Carter M, Carter L, Parry M, Franklin L, Marais R, Blackhall F, Dive C, Brady G.

Mol Oncol. 2017 Dec;11(12):1687-1697. doi: 10.1002/1878-0261.12113. Epub 2017 Oct 24.

33.

twoddpcr: an R/Bioconductor package and Shiny app for Droplet Digital PCR analysis.

Chiu A, Ayub M, Dive C, Brady G, Miller CJ.

Bioinformatics. 2017 Sep 1;33(17):2743-2745. doi: 10.1093/bioinformatics/btx308.

34.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

35.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

36.

Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models.

Khandelwal G, Girotti MR, Smowton C, Taylor S, Wirth C, Dynowski M, Frese KK, Brady G, Dive C, Marais R, Miller C.

Mol Cancer Res. 2017 Aug;15(8):1012-1016. doi: 10.1158/1541-7786.MCR-16-0431. Epub 2017 Apr 25.

37.

SnapShot: Circulating Tumor Cells.

Dive C, Brady G.

Cell. 2017 Mar 23;169(1):176. doi: 10.1016/j.cell.2017.03.017. No abstract available.

38.

SnapShot: Circulating Tumor Cells.

Dive C, Brady G.

Cell. 2017 Feb 9;168(4):742-742.e1. doi: 10.1016/j.cell.2017.01.026. Erratum in: Cell. 2017 Mar 23;169(1):176.

39.

Cancer Moonshot Connecting International Liquid Biopsy Efforts Through Academic Partnership.

Dive C, Shishido SN, Kuhn P.

Clin Pharmacol Ther. 2017 May;101(5):622-624. doi: 10.1002/cpt.657. Epub 2017 Mar 22. Review.

PMID:
28182274
40.

Novel risk models for early detection and screening of ovarian cancer.

Russell MR, D'Amato A, Graham C, Crosbie EJ, Gentry-Maharaj A, Ryan A, Kalsi JK, Fourkala EO, Dive C, Walker M, Whetton AD, Menon U, Jacobs I, Graham RL.

Oncotarget. 2017 Jan 3;8(1):785-797. doi: 10.18632/oncotarget.13648.

41.

Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer.

Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, Li Y, Burt DJ, Antonello J, Morrow CJ, Hodgkinson CL, Morris K, Priest L, Carter M, Miller C, Hughes A, Blackhall F, Dive C, Brady G.

Nat Med. 2017 Jan;23(1):114-119. doi: 10.1038/nm.4239. Epub 2016 Nov 21.

PMID:
27869802
42.

Vasculogenic mimicry in small cell lung cancer.

Williamson SC, Metcalf RL, Trapani F, Mohan S, Antonello J, Abbott B, Leong HS, Chester CP, Simms N, Polanski R, Nonaka D, Priest L, Fusi A, Carlsson F, Carlsson A, Hendrix MJ, Seftor RE, Seftor EA, Rothwell DG, Hughes A, Hicks J, Miller C, Kuhn P, Brady G, Simpson KL, Blackhall FH, Dive C.

Nat Commun. 2016 Nov 9;7:13322. doi: 10.1038/ncomms13322.

43.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

44.

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.

Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S, Garner G, Ayub M, Wood S, Rothwell DG, Fusi A, Wallace A, Brady G, Dive C, Dhomen N, Lorigan P, Marais R.

Ann Oncol. 2016 Oct;27(10):1959-65. doi: 10.1093/annonc/mdw278. Epub 2016 Aug 8.

45.

Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC.

Crosbie PA, Shah R, Krysiak P, Zhou C, Morris K, Tugwood J, Booton R, Blackhall F, Dive C.

J Thorac Oncol. 2016 Oct;11(10):1793-7. doi: 10.1016/j.jtho.2016.06.017. Epub 2016 Jul 25.

46.

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

Jahchan NS, Lim JS, Bola B, Morris K, Seitz G, Tran KQ, Xu L, Trapani F, Morrow CJ, Cristea S, Coles GL, Yang D, Vaka D, Kareta MS, George J, Mazur PK, Nguyen T, Anderson WC, Dylla SJ, Blackhall F, Peifer M, Dive C, Sage J.

Cell Rep. 2016 Jul 19;16(3):644-56. doi: 10.1016/j.celrep.2016.06.021. Epub 2016 Jun 30.

47.

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.

Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC.

Br J Cancer. 2016 Jul 12;115(2):228-35. doi: 10.1038/bjc.2016.194. Epub 2016 Jun 28.

48.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

49.

Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.

Potter DS, Galvin M, Brown S, Lallo A, Hodgkinson CL, Blackhall F, Morrow CJ, Dive C.

Mol Cancer Ther. 2016 Jun;15(6):1248-60. doi: 10.1158/1535-7163.MCT-15-0885. Epub 2016 Mar 29.

50.

PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.

Kirwan CC, Bundred NJ, Castle J, Clarke R, Dive C, Morris J, Holcombe C, Harvey JR.

Thromb Res. 2016 Apr;140 Suppl 1:S189-90. doi: 10.1016/S0049-3848(16)30169-4. Epub 2016 Apr 8.

PMID:
27161723

Supplemental Content

Support Center